The inhibitory effect of a conjugate of human immunoglobulin G and melphalan, K18, on DNA synthesis of human tumor cells.
K18 is a conjugate of human immunoglobulin G and melphalan and has been reported to accumulate selectively in the tumor. In the present study, the in vitro antitumor effect of K18 was assessed in a total of 107 fresh human tumors by DNA synthesis (3H-thymidine incorporation) inhibition assay, and compared with that of other drugs. Human tumor cells showed a variety of sensitivities to K18: gastric, breast, pancreatic, liver or ovarian cancer cells were comparatively sensitive to K18, while esophageal or colorectal cancers were insensitive. These results suggest that the conjugation of melphalan with IgG did not reduce the antitumor activity of melphalaln and that K18 may be applied in cancer chemotherapy instead of melphalan.